# Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)

> **NCT03561402** · — · COMPLETED · sponsor: **McGill University** · enrollment: 24 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Teriflunomide

## Key facts

- **NCT ID:** NCT03561402
- **Lead sponsor:** McGill University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03561402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03561402, "Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03561402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*